With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.

2.

Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.

3.

Treating advanced prostate cancer

4.

Older Adults With Advanced Cancer Prioritize Quality of Life

5.

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot